Key Points
- Medtronic CEO Geoffrey Martha sold 50,000 shares at an average price of $95, generating $4.75 million. The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan, leaving him with 277,866 shares.
- Medtronic shares recently traded at $94.79, while the company reported quarterly earnings and revenue above analyst expectations. The company also pays a quarterly dividend of $0.72, equivalent to a 3.0% annual yield.
- Analyst sentiment remains moderately positive, with 17 Buy, 10 Hold and one Sell rating and an average price target of $102.88. However, tariffs, inflation, currency pressures and recent institutional selling could weigh on the stock.
Medtronic PLC (NYSE:MDT - Get Free Report) EVP Michael Marinaro sold 10,420 shares of Medtronic stock in a transaction that occurred on Thursday, October 15th. The stock was sold at an average price of $96.00, for a total transaction of $1,000,320.00. Following the transaction, the executive vice president owned 105,916 shares in the company, valued at approximately $10,167,936. The trade was a 8.96% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Medtronic Stock Down 0.7%
NYSE:MDT traded down $0.66 during trading hours on Friday, hitting $94.79. 30,274,266 shares of the stock traded hands, compared to its average volume of 33,123,818. The firm has a 50 day moving average price of $91.03 and a 200 day moving average price of $85.01. The firm has a market cap of $121.25 billion, a price-to-earnings ratio of 23.35, a PEG ratio of 2.17 and a beta of 0.55. Medtronic PLC has a fifty-two week low of $73.31 and a fifty-two week high of $106.33. The company has a current ratio of 2.07, a quick ratio of 1.54 and a debt-to-equity ratio of 0.50.
Medtronic (NYSE:MDT - Get Free Report) last issued its quarterly earnings results on Tuesday, September 1st. The medical technology company reported $1.45 earnings per share for the quarter, beating analysts' consensus estimates of $1.39 by $0.06. The business had revenue of $9.76 billion for the quarter, compared to the consensus estimate of $9.55 billion. Medtronic had a return on equity of 14.78% and a net margin of 13.93%. Medtronic's revenue for the quarter was up 13.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.26 earnings per share. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. Equities research analysts anticipate that Medtronic PLC will post 5.98 earnings per share for the current year.
Medtronic Dividend Announcement
The firm also recently disclosed a quarterly dividend, which was paid on Friday, October 16th. Shareholders of record on Friday, September 25th were given a dividend of $0.72 per share. The ex-dividend date was Friday, September 25th. This represents a $2.88 dividend on an annualized basis and a yield of 3.0%. Medtronic's dividend payout ratio (DPR) is presently 70.94%.
Wall Street Analysts Forecast Growth
MDT has been the topic of a number of research reports. Piper Sandler reiterated a "neutral" rating on shares of Medtronic in a report on Wednesday. Royal Bank Of Canada restated an "outperform" rating and set a $118.00 price target on shares of Medtronic in a report on Wednesday, September 2nd. Needham & Company LLC reaffirmed a "buy" rating on shares of Medtronic in a research report on Thursday, September 17th. TD Cowen reaffirmed a "buy" rating and set a $110.00 price objective on shares of Medtronic in a research report on Wednesday, September 30th. Finally, Mizuho set a $115.00 price objective on shares of Medtronic in a research note on Wednesday, September 2nd. Seventeen investment analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, Medtronic has an average rating of "Moderate Buy" and a consensus target price of $102.88.
Read Our Latest Stock Report on Medtronic
Institutional Trading of Medtronic
A number of institutional investors have recently bought and sold shares of MDT. Monetary Solutions Ltd purchased a new stake in shares of Medtronic during the 4th quarter worth about $27,000. Activest Wealth Management lifted its holdings in shares of Medtronic by 470.9% during the 3rd quarter. Activest Wealth Management now owns 314 shares of the medical technology company's stock valued at $27,000 after buying an additional 259 shares during the last quarter. IAG Wealth Partners LLC acquired a new stake in shares of Medtronic during the 2nd quarter valued at about $30,000. Pin Oak Investment Advisors Inc. bought a new stake in shares of Medtronic in the 2nd quarter valued at approximately $32,000. Finally, Global Assets Advisory LLC bought a new stake in shares of Medtronic in the 1st quarter valued at approximately $36,000. Institutional investors and hedge funds own 82.06% of the company's stock.
Key Headlines Impacting Medtronic
Here are the key news stories impacting Medtronic this week:
- Positive Sentiment: Medtronic’s Stealth AXiS surgical system and Corsano multi-parameter wearable were named to TIME’s 2026 Best Inventions list. The recognition supports the company’s innovation strategy and could improve visibility for its surgical and monitoring businesses. Medtronic Named to TIME Best Inventions of 2026
- Positive Sentiment: Medtronic continues expanding in cardiac ablation, robotics, hypertension and digital surgery. Recent sales and profit growth, along with a raised fiscal outlook, provide support for the longer-term investment case. Is Medtronic Stock a Buy Now That Sales Growth Has Picked Up?
- Neutral Sentiment: Medtronic completed the separation of MiniMed, exchanging its remaining shares and leaving the diabetes-technology company fully independent. The transaction simplifies MDT’s portfolio and may allow greater focus on higher-growth medical-device businesses, but it also removes direct ownership of MiniMed and changes the company’s revenue mix. Medtronic Completes Separation of MiniMed Group
- Negative Sentiment: Analyst sentiment remains cautious: Piper Sandler assigned a Hold rating, while Barclays began coverage at Equal Weight. These ratings suggest limited near-term upside after MDT’s recent advance. Medtronic Receives a Hold from Piper Sandler
- Negative Sentiment: Tariffs, inflation and unfavorable currency movements could pressure Medtronic’s margins. ETFs also reportedly sold $222.5 million of MDT shares on October 13, adding a potential short-term technical headwind. Is it Apt to Retain Medtronic Stock in Your Portfolio Now?
About Medtronic
(
Get Free Report)
Medtronic plc is a global medical technology company that develops and manufactures devices, therapies and healthcare solutions for treating chronic and acute conditions. Its products are used in areas including cardiac and vascular care, neuroscience, medical and surgical procedures, and diabetes management.
The company's portfolio includes pacemakers, implantable cardioverter-defibrillators, cardiac ablation systems, stents and other cardiovascular products; neuromodulation systems, deep-brain stimulation devices and spinal technologies; surgical instruments, robotic-assisted surgery systems and gastrointestinal diagnostic tools; and insulin pumps and related diabetes technologies.
Medtronic traces its origins to 1949, when Earl Bakken and Palmer Hermundslie founded the company in Minneapolis, Minnesota.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
